Immunotherapy, Год журнала: 2025, Номер unknown, С. 1 - 3
Опубликована: Май 12, 2025
Язык: Английский
CA A Cancer Journal for Clinicians, Год журнала: 2023, Номер 74(2), С. 187 - 202
Опубликована: Окт. 25, 2023
The progression of cancer involves a critical step in which malignant cells escape from control by the immune system. Antineoplastic agents are particularly efficient when they succeed restoring such (immunosurveillance) or at least establish an equilibrium state that slows down disease progression. This is true not only for immunotherapies, as checkpoint inhibitors (ICIs), but also conventional chemotherapy, targeted anticancer agents, and radiation therapy. Thus, therapeutics stress kill while provoking tumor-targeting response, referred to immunogenic cell death, useful combination with ICIs. Modern oncology regimens increasingly using combinations, chemoimmunotherapy, well combinations multiple However, latter generally associated severe side effects compared single-agent Of note, success these combinatorial strategies against locally advanced metastatic cancers now spurring successful attempts move them past postoperative (adjuvant) setting preoperative (neoadjuvant) setting, even patients operable cancers. Here, authors critically discuss importance immunosurveillance modern clinical management.
Язык: Английский
Процитировано
72
Nature Cancer, Год журнала: 2024, Номер 5(4), С. 557 - 571
Опубликована: Фев. 15, 2024
Язык: Английский
Процитировано
42
Autoimmunity Reviews, Год журнала: 2024, Номер 23(7-8), С. 103589 - 103589
Опубликована: Июль 1, 2024
Язык: Английский
Процитировано
10
Frontiers in Immunology, Год журнала: 2025, Номер 16
Опубликована: Март 5, 2025
Chronic inflammation of the intestine is a significant risk factor in development colorectal cancer. The emergence colitis and cancer complex, multifactorial process involving chronic inflammation, immune regulation, tumor microenvironment remodeling. Macrophages represent one most prevalent cells play pivotal role maintaining intestinal health colitis-associated colon (CAC). are activated mainly two ways resulted three phenotypes: classically macrophages (M1), alternatively (M2). characteristic these pro-inflammatory M1 anti-inflammatory M2 types, which different roles at stages disease. During progresses to cancer, proportion gradually increases. secrete cytokines such as IL-10 TGF-β, promote angiogenesis matrix remodeling, create favorable conditions for cell proliferation, infiltration, migration. Therefore, macrophage polarization has dual effect on progression CAC. combination immunotherapy with reprogrammed anti-tumor drugs may provide an effective means enhancing therapeutic effect. It promising avenue developing novel treatments In this review, we focus CAC review targets relevant targeting
Язык: Английский
Процитировано
1
Annals of Oncology, Год журнала: 2024, Номер unknown
Опубликована: Сен. 1, 2024
Язык: Английский
Процитировано
6
Neurology Neuroimmunology & Neuroinflammation, Год журнала: 2023, Номер 11(1)
Опубликована: Окт. 26, 2023
Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy but come with immune-related adverse events (irAEs) that provide a novel challenge for treating physicians. Neuromuscular irAEs, including myositis, myasthenia gravis (MG), and demyelinating polyradiculoneuropathy, lead to significant morbidity mortality.
Язык: Английский
Процитировано
13
Journal of Cardiovascular Pharmacology, Год журнала: 2024, Номер 83(5), С. 364 - 376
Опубликована: Фев. 9, 2024
Myocarditis is an inflammatory disease of the myocardium characterized by a great heterogeneity presentation and evolution. Treatment myocarditis often supportive, evidence for immunosuppression scarce debated. Conventional treatment based on clinical presentation, ranging from conservative to advanced mechanical assist devices. In this setting, immunomodulation therapies are mostly reserved patients presenting with major syndromes. review, we will summarize current strategies conventional immunosuppressive treatments acute myocarditis.
Язык: Английский
Процитировано
5
Rheumatic Disease Clinics of North America, Год журнала: 2024, Номер 50(2), С. 147 - 159
Опубликована: Фев. 23, 2024
Язык: Английский
Процитировано
5
Clinical and Translational Medicine, Год журнала: 2024, Номер 14(3)
Опубликована: Март 1, 2024
Abstract The emergence of immune checkpoint inhibitors (ICIs) has heralded a transformative era in the therapeutic landscape non‐small cell lung cancer (NSCLC). While ICIs have demonstrated clinical efficacy portion patients with NSCLC, these treatments concurrently precipitate spectrum immune‐related adverse events (irAEs), encompassing mild to severe manifestations, collectively posing risk significant organ damage. Consequently, there exists an imperative augment our comprehension pathophysiological underpinnings irAEs and formulate more efficacious preventive ameliorative strategies. In this comprehensive review, we delineate presentation organ‐specific NSCLC provide in‐depth analysis recent advancements understanding mechanisms driving ICI‐induced toxicity. Furthermore, discuss potential strategies targets for ameliorating irAEs. Ultimately, review aims furnish valuable insights guide further research endeavours context patients.
Язык: Английский
Процитировано
5
Rheumatic Disease Clinics of North America, Год журнала: 2024, Номер 50(2), С. 255 - 267
Опубликована: Апрель 24, 2024
Язык: Английский
Процитировано
5